Skip Navigation
Search Menu
Find an Expert


Andy Tompkins, M.D.

David Andrew Tompkins, M.D.

Photo of Dr. Andy Tompkins, M.D.


Expertise: Addiction Medicine, Addiction Psychiatry Services, Adult Psychiatry, Pain Management, Psychiatry, Psychiatry and Behavioral Sciences , Substance Abuse, Substance Abuse Research more

Research Interests: Treatment of pain in persons with a history of addiction; Medications development for the treatment of addiction; identification of chronic pain patients at risk for opioid misuse/addiction more

Request an Appointment

I live in Maryland

Request an appointment through MyChart!

I live outside of Maryland

Request Appointment

I live outside of the United States

Request Appointment


Johns Hopkins Bayview Medical Center
Appointment Phone: 410-550-0104

301 Mason Lord Drive
E 317
Baltimore, MD 21224 map
Phone: 410-550-1365

Contact for Research Inquiries

Behavioral Pharmacology Research Unit
5510 Nathan Shock Drive
Baltimore, MD 21224 map


My primary research interest is to better understand the experience, measurement and treatment of pain in persons with a history of or current substance use disorders. To this aim, I have a NIDA funded career development award to quantify analgesia and abuse potential of standard intravenous opioid medications given to persons maintained on methadone or buprenorphine. I am developing a novel experimental pain testing battery to be used in future clinical trials aimed at optimizing pain treatment in this population. Experimental pain techniques utilized in my lab include (not an exhaustive list) cold pressor testing, thermal pain testing, algometer pressure pain testing, mechanical suprathreshold pain testing, and conditioned pain modulation. I have also used these techniques in an attempt to model prospectively the development of opioid induced hyperalgesia and opioid withdrawal associated hyperalgesia.  My second main area of interest is in developing novel medications for the treatment of substance use disorders; and I have collaborated on single and multisite clinical trials examining a cocaine vaccine and topiramate for the treatment of cocaine use disorders, tramadol extended-release for the treatment of opioid withdrawal, and zolpidem extended-release for the treatment of cannabis use disorders. Lastly, I am interested in better assessment of opioid withdrawal in persons with a history of opioid use disorders and in persons maintained on opioids for the treatment of chronic pain without a history of addiction. To this end, I validated the Clinical Opiate Withdrawal Scale (COWS) and developed a comprehensive assessment battery to look at spontaneous opioid withdrawal. more

Departments / Divisions



  • MD, New York Medical College (2004)


  • Johns Hopkins University School of Medicine / Psychiatry (2008)


  • Johns Hopkins University School of Medicine / Behavioral Pharmacology (2010)

Board Certifications

  • American Board of Psychiatry & Neurology / Psychiatry (2009)

Additional Training

  • Diplomate in Addiction Medicine, American Board of Addiction Medicine (2012)

Research & Publications

Clinical Trial Keywords

Quantitative Sensory Testing, Cocaine Vaccine

Selected Publications

Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, Levin FR, Mariani JJ, Stitzer M, Tompkins DA, Rotrosen J, Thakkar V, Smoak B, Kampman K. "Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial." Drug Alcohol Depend. 2014 Jul; 140:42-7. PMID: 24793366.

Tompkins DA, Smith MT, Bigelow GE, Moaddel R, Vattem Venkata SL, Strain EC. "The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males." Clin J Pain. 2014 Jan; 30(1):36-45.

Byne W, Bradley SJ, Coleman E, Eyler AE, Green R, Menvielle EJ, Meyer-Bahlburg HFL, Pleak RR, Tompkins DA. Report of the American Psychiatric Association Task Force on Treatment of Gender Identity Disorder. Arch Sex Behav. 2012 Aug; 41(4):759-96.

Tompkins DA, Campbell CM. "Opioid induced hyperalgesia: clinically relevant or extraneous research phenomenon?" Curr Pain Headache Rep 2011; 15(2):129-36.

Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone." Psychopharm 2010 Jul; 210(4)471-80.

Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. "Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument." Drug Alc Dep. 2009 Nov; 105(1-2)154-9.

Activities & Honors


  • American Pain Society, 2009
  • American Psychiatric Association, 2001

    I am the current Deputy Representative to the APA Assembly for the Caucus of Gay Lesbian and Bisexual Psychiatrists. I am also a Fellow of the APA since 2015.

  • Association of Gay and Lesbian Psychiatrists
  • College on Problems of Drug Dependence
  • Group for the Advancement of Psychiatry
  • International Association for the Study of Pain
Is this you? Edit Profile